Figure 6.

(A) Transduction efficiency of Ad/LacZ in MKN-45 cells in vivo. Twenty six days after tumour cell inoculation, mice were injected with Ad/LacZ at 3×10¹⁰ particles into the peritoneal cavity. Forty eight hours after inoculation, mice were killed and 5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside (X-gal) staining was performed. Original magnification, ×40. (B, C) On days 6, 7, and 8 after inoculation, mice received no treatment (Control), Ad/LacZ, Ad/p53, or Ad/Bax at 2×10¹⁰ particles. (B) Macroscopic appearance of peritoneal dissemination after treatment on day 24 after inoculation. Arrows, disseminated tumour. (C) Total number (left) and weight (right) of disseminated tumours. Values represent the means (SD) of eight mice per group. Treatment with Ad/Bax differed significantly from that in the other groups (p<0.01). (D) Survival of mice bearing peritoneal dissemination of MKN-45 tumours treated with intraperitoneal injection of Ad/Bax. Survival was monitored over time after tumour injection and plotted as a Kaplan-Meier plot.